MAPK3 and neoplasm: As a major mediator of tumor-associated inflammation, SPP1 has been proven to be related to enzalutamide resistance by activating the PI3K/AKT and ERK1/2 signaling pathways in CRPC, and promoting the invasion and metastasis of CRPC (59).